◆神戸市兵庫区◆　地域急性期病院

• 連続休暇
• 開業支援
• 高額年俸
• 院長クラス
• 週4以下
• オンコールなし

【兵庫県内】新規開院クリニック／訪問診療／管理医師

勤務地

兵庫県内

給与

2200万円 応相談

募集科目

全科目不問、内科全般（科目不問）、一般内科、外科全般（科目不問）、一般外科

勤務内容

在宅
◆訪問診療
・看護部同行・運転不要

＜オンコール体制＞
・ポイント制（平日夜間：1pt、土曜夜間：1.5pt、日曜・祝日の通し：3pt）
・ファーストコールは看護師が対応
・運転は看護師が対応

新規開院のため、開業当初は担当患者数が少なく、出動件数も比較的少ないことが見込まれます。
立ち上げ期ならではの環境で、無理なく地域医療の基盤づくりに携わっていただけます。
また、患者数の増加に伴い医師の増員を予定しており、オンコール回数も段階的に減少していく見込みです。

• 高額年俸
• 院長クラス
• 週4以下

【姫路】新規開設予定／訪問診療クリニック／管理医師募集　

勤務地

兵庫県姫路市

給与

1600万円 ～ 2000万円 応相談

募集科目

全科目不問、内科全般（科目不問）、一般内科、外科全般（科目不問）、一般外科

勤務内容

在宅
訪問診療、勤務時間内の緊急コール及び緊急往診

訪問診療を中心に定期診療および往診をお願いします。
近隣との多職種連携に必要な活動にご協力いただくこともございます。

◆訪問診療及び往診
担当患者数：100～200人（施設の場合：1名あたり0.5人換算）
※患者数が増えてきた際の想定人数
居宅 ：約5～6名/半日
施設 ：25～30名/半日

～1日のスケジュール例～
＜午前中＞
・1日の訪問スケジュールの確認
　(各患者様の状態や、確認事項を朝一で確認頂きます)
・訪問
　例：居宅4～5か所(1軒10～15分程度です)

＜お昼＞
・一度クリニックに戻り休憩

＜午後＞
・施設へ訪問
　施設では5～6名程度該当の患者様を診ていきます。
　診療内容については午前中の業務参照

＜夕方＞
・クリニックへ戻る
　1日のカルテや情報をまとめる

＜18:00＞
・退社

• 当直なし
• 週4以下
• オンコールなし
• セカンドキャリア

【兵庫県神戸市】介護医療院

勤務地

兵庫県神戸市

給与

1000万円 ～ 1300万円 応相談

募集科目

全科目不問、内科全般（科目不問）、一般内科、老人内科

勤務内容

病棟
・受持ち：40～45名程度

※早出・居残り有り

【兵庫県】MD求人

勤務地

兵庫県内

給与

1400万円 応相談

募集科目

一般内科、小児科、その他（アレルギー科、免疫科）、製薬会社

勤務内容

その他
対象科目：内科、小児科、アレルギー科、免疫科

Basic purpose of the job
Senior CPhL-Asia supports the clinical development in Asia of new drugs and further development of approved drugs with emphasis on the design and execution of the Clinical Pharmacology (CP)development strategy.
CPhL-Asia is accountable and responsible for communicating with regulatory authorities on CP topics and for CP aspects of drug submission in Asia (e.g., submission summaries).
CPhL-Asia may act as trial clinical Pharmacologist (TCP; see TCP job profile) for clinical studies in their own project or outside of their own projects.
CPhL-Asia may serve as Clin Pharm representative within various teams in Asia (Japan/China) in support of early integration of Japan/China into global development program. Post PoCP, they may serve as CP and TMCP representative in various Asian teams until submission and launch. CPhL-Asia will also serve as main TMCP representatives in all PMO projects in Asia.

Accountabilities
Ensure timely delivery of state-of-the-art Clinical Pharmacology scientific concepts for decision making throughout clinical drug development and registration in Asia including all necessary processes and documentation.
Ensures timely delivery of state-of-the-art Clinical Pharmacology strategy development and implementation.
Senior CPhL-Asia is responsible for defining the CP strategy (for instance, defining the drug-drug interaction liability or formulation development strategy for modified release) of assigned project. CPhL-Asia is also responsible for refining the CP strategy in a timely manner as new data become available during drug development. As part of the strategy, CPhL-Asia may define CP aspects in a clin trial protocol and for an eventual submission and further phase IV activities.
Senior CPhL-Asia contributes to the Clin Pharm section of official documents (e.g., Information Brochure (IB), label); CPhL-Asia engages with regulatory agencies on matters pertaining to CP during drug development and are responsible for supporting Asian submission and post-submission activities with Clin Pharm and Biopharm expertise.
Clinical development project representative
Act as Clin Pharm representative in trial and project teams and regulatory meetings.
CPhL-Asia serves as Clin Pharm representative within various teams in support of early integration of Japan/China into global development program. Post PoCP, they may serve as CP and TMCP representative in various Asian teams until submission and launch. CPhL-Asia may also serve as main TMCP representatives in all PMO projects in Asia.
When delegating a trial to TCP, a CPhL-Asia is expected to ensure that adequate amount of information on the project and trial are provided to the TCP.
For instance, a CPhL-Asia is expected to discuss study design and project standards with the TCP.
A CPhL-Asia may function as a TCP in certain studies or projects.
Driving science and innovation
CPhL-Asia leads clinical development trial and project overarching topics from TMCP (e.g. by focus group).
CPhL-Asia represents Clinical Pharmacology or TMCP in internal and external initiatives/working groups.
CPhL-Asia continuously scouts, evaluates (incl piloting) and implements new methods and strategies in the area of Clinical Pharmacology.
Strategic partnerships:
CPhL-Asia implements collaborations and strategic partnerships with external bodies. They organize and manage projects with external organizations (e.g. CROs, ARO).
CPhL-Asia may serve as subject matter expert (CP, Biopharm) in in –or outlicensing activities

Functional processes:
CPhL-Asia continuously develops and refines further functional processes and infrastructure.
CPhL-Asia is CP (CP and Biopharm) experts and may offer this expertise to other interface functions (e.g, Toxicology, Pharmacovigilance, Customer Information, Marketing, Regulatory Affairs) or to support internal or external working groups.
CPhL-Asia presents results internally and externally as well as contributes to scientific publications.

Compliance (incl GCP):
CPhL-Asia follows all ICH GCP, other relevant authority regulations and internal guidance to protect the rights, safety and wellbeing of trial subjects, including sample chain of custody, data privacy and data integrity. In addition, obligations outside the field of clinical studies, such as EHS, Pharmacovigilance, anti-corruption, BI-internal guidance should be followed.